Drug Information

Drug General Information
Drug ID
D04OSA
Former ID
DIB007110
Drug Name
AZD-3839
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 1 [523465], [541975]
Company
AstraZeneca plc
Structure
Download
2D MOL

3D MOL
Formula
C24H18F3N5
InChI
InChI=1S/C24H18F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22-23,32H,28H2/t23?,24-/m0/s1
InChIKey
QXKYWSDUVAJHNZ-CGAIIQECSA-N
PubChem Compound ID
60210951
PubChem Substance ID
144241748, 178103513, 208012738
Target and Pathway
Target(s) Beta-secretase Target Info Inhibitor [532073]
References
Ref 523465ClinicalTrials.gov (NCT01348737) Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers. U.S. National Institutes of Health.
Ref 541975(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6931).
Ref 532073Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.